Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Access to care linked to better outcomes in black men with prostate cancer

Halabi et al, George et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology) Abstracts LBA5005 and LBA5009.

Key clinical point: Apparent racial disparities in prostate cancer care may be reduced or eliminated with proper care and access to clinical trials.

Major finding: In a pooled analysis, black men with advanced prostate cancer treated with docetaxel prednisone had a 19% lower risk for death than white men,

Study details: Pooled analysis of 9 randomized phase III trials with a total of 8,452 men and a prospective trial with 100 men with advanced prostate cancer.

Disclosures: The study by Halabi et al was funded by Congressionally Directed Medical Research Programs. The study by George et al was funded by Janssen. Dr. Halabi disclosed a consulting or advisory role with Tokai Pharmaceuticals, Eisai, and Bayer, and travel expenses from Bayer. Dr. George disclosed consulting/advising with Janssen and several other pharmaceutical companies, in addition to speakers’ bureau, travel expenses, and honoraria from various companies. He has also received institutional research funding from Exelixis, Genentech/Roche, Janssen Oncology, Novartis, Pfizer, Astellas Pharma, Bristol-Myers Squibb, Millennium, Acerta Pharma, Bayer, Dendreon, and Innocrin Pharma.

Source: Halabi et al, George et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology) Abstracts LBA5005 and LBA5009.

Read the article.

Citation:

Halabi et al, George et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology) Abstracts LBA5005 and LBA5009.

This Week's Must Reads

Liquid biopsy aids assessment in advanced imatinib-resistant GIST, George S et al. ASCO 2018. Abstract 11511.

Rapid therapy changes fall short for metastatic GIST, Serrano-Garcia C et al. ASCO 2018, Abstract 11510.

Estimated conditional OS shows upfront TKI benefit in mRCC, Kang M et al. J Urol. 2018 June 22. doi: 10.1016/j.juro.2018.06.030

Indolent course found in rare clear cell papillary RCC , Chen W-J et al. J Chinese Med Assoc. 2018 July 20 doi: 10.1016/j.jcma.2018.04.005

Must Reads in Genitourinary Cancer

Estimated conditional OS shows upfront TKI benefit in mRCC, Kang M et al. J Urol. 2018 June 22. doi: 10.1016/j.juro.2018.06.030

Indolent course found in rare clear cell papillary RCC , Chen W-J et al. J Chinese Med Assoc. 2018 July 20 doi: 10.1016/j.jcma.2018.04.005

Study: Clear cell papillary RCC has indolent course, Chen W-J et al. J Chinese Med Assoc. 2018 July 20 doi: 10.1016/j.jcma.2018.04.005

Combo therapy after disease progression no advantage in chemotherapy-naïve metastatic castration-resistant prostate cancer, Attard G et al. Journal of Clinical Oncology; published online 20 July 2018. http://ascopubs.org/doi/abs/10.1200/JCO.2018.77.9827

In metastatic hormone-sensitive prostate cancer, prior local therapy is linked to improved survival, Abdel-Rahman O and Cheung W. Clinical Genitourinary Cancer; published online 21 July 2018 https://doi.org/10.1016/j.clgc.2018.07.007